With Proper Evidence, Biomarker Testing Can Help Reduce Health Care Costs
-
Jun 12, 2025
As the number of biomarker tests continues to rapidly grow, some health plans may struggle with coverage of them. A recent Zitter Insights survey found that 30% of commercial and Medicare payers do not provide coverage of companion diagnostics — a type of biomarker testing — for their members. But payer coverage of many of these tests can lead to lower health care costs. With that in mind, many states are mandating coverage of biomarker testing for state-regulated plans, with New Jersey recently becoming the latest one to do so.
On April 23, New Jersey Lieutenant Governor and Secretary of State Tahesha Way signed A-4163/S-3098 into law, mandating that state-regulated health insurance plans, Medicaid, the State Health Benefits Program and the School Employees’ Health Benefits Program cover “biomarker precision medical testing…for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a disease or condition, excluding asymptomatic screening, to guide treatment decisions of a subscriber when the test is supported by medical and scientific evidence.”
Read more© 2025 MMIT
